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Abstract
Purpose Vasoplegia often complicates on-pump cardiac surgery. Systemic inflammatory response induced by extracorporeal 
circulation represents the major determinant, but adrenal insufficiency and postoperative vasopressin deficiency may have 
a role. Pathophysiological meaning of perioperative changes in endocrine markers of hydro-electrolyte balance has not still 
fully elucidated. Objectives of the present research study were to estimate the incidence of vasoplegia in a homogeneous 
cohort of not severe cardiopathic patients, to define the role of presurgical adrenal insufficiency, to evaluate copeptin and 
NT-proBNP trends in the perioperative.
Methods We conducted a prospective cohort study in the cardiac intensive care unit of a tertiary referral center. We evalu-
ated 350 consecutive patients scheduled for cardiac surgery; 55 subjects completed the study. Both standard and low-dose 
corticotropin stimulation tests were performed in the preoperative; copeptin and NT-proBNP were evaluated in the preopera-
tive (T0), on day 1 (T1) and day 7 (T2) after surgery.
Results Nine subjects (16.3%) developed vasoplegic syndrome with longer bypass and clamping time (p < 0.001). Reduced 
response to low-dose ACTH test was not associated to vasoplegia. Preoperative copeptin > 16.9 pmol/L accurately predicted 
the syndrome (AUC 0.86, 95% CI 0.73–0.94; OR 1.17, 95% CI 1.04–1.32). An evident correlation was observed at 7 days 
postoperative between NT-proBNP and copeptin (r 0.88, 95% CI 0.8–0.93; p < 0.001).
Conclusion Preoperative impaired response to low-dose ACTH stimulation test is not a risk factor for post-cardiotomic vaso-
plegia; conversely, higher preoperative copeptin predicts the complication. On-pump cardiac surgery could be an interesting 
model of rapid heart failure progression.
Keywords Copeptin · Shock · Cardiac surgery · Adrenal insufficiency · NT-proBNP · Vasopressin
Introduction
Postoperative vasodilatory shock is a common complica-
tion after major cardiac surgery. It occurs in 5–45% of the 
procedures and is observed mostly among on-pump inter-
vention [1–4]. This condition has been defined as post-car-
diotomy vasoplegic syndrome (PCVS) and is characterized 
by reduced vascular tone, tissue hypoperfusion and meta-
bolic acidosis [1, 4, 5]. PCVS represents the second cause 
of vasoplegic shock after sepsis; other well-known associ-
ated conditions are major surgical interventions (e.g., organ 
transplantation), multi-organ failure as a result of burns or 
multiple traumas, severe pancreatitis [1].
The factors responsible for impaired vasomotor tone after 
cardiopulmonary bypass (CPB) are only partially under-
stood. An increased incidence of PCVS in patients with a 
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preoperative history of congestive heart failure (HF) has 
been described and previously attributed to vasodilatory 
factors such as tumor necrosis factor and nitric oxide [6]. 
Preoperative use of angiotensin-converting enzyme (ACE) 
inhibitors has been also independently associated with an 
increased risk of vasodilatory shock after CPB [2, 6].
Patients undergoing CPB and extracorporeal circula-
tion often experience a systemic inflammatory response 
syndrome (SIRS) which was associated with both adverse 
clinical outcomes and alterations in hypothalamic–pitui-
tary–adrenal (HPA) axis function [7, 8]. On this basis, an 
endocrinological mechanism supposed to be implicated in 
PCVS is a CPB-related acquired adrenal insufficiency (AI) 
[8, 9]. Glucocorticoids are necessary for the physiological 
action of angiotensin II, epinephrine and nor-epinephrine 
(NE) and, consequently, for maintaining an adequate vas-
cular tone in response to surgical stress [10]. The incidence 
of post-cardiotomy AI is estimated in 38–60% of surgical 
procedures, depending on the criteria used for the diagno-
sis, and is associated to vasopressor resistance with neces-
sity of a prolonged amino-pharmacological support [8]. No 
evidence about the role of a presurgical HPA axis impair-
ment or exhaustion in the development of PCVS is currently 
available.
In this setting, vasopressin (AVP) and natriuretic peptides 
(NPs) represent other major and interdependent regulators of 
both hydro-electrolyte balance and vascular tone.
The role of circulating AVP levels in the hemodynam-
ics of PCVS patients is complex. In HF, a persistent AVP 
secretion, mainly due to the reduced tonic inhibition by high-
pressure baroreceptors, is involved in the water retention 
process and in the development of hypotonic hyponatremia 
[11]. On the other hand, a dysregulation of AVP V1 recep-
tors (V1R), physiologically responsible both for a calcium-
mediated vasoconstriction mechanism and for the regulatory 
feedback on baroreceptor sensitivity, has been hypothesized 
in critically ill patients and HF [12, 13]. Furthermore, a 
blunted AVP increase in the early postoperative of patients 
developing PCVS has been reported, and the cause was 
attributed to the progressive depletion of the peptide stored 
in hypothalamic neurogranules under conditions of chronic 
hyperstimulation [5]. Consequently, in the last years, it has 
been assumed that a relative AVP insufficiency may contrib-
ute to the failure in restoring vascular tone in post-cardiac 
surgery vasodilatory shock [13–15].
The physiological action of NPs is substantially oppo-
site to that of AVP, promoting natriuresis and vasodila-
tion, also reducing hypothalamic AVP secretion; for its 
part, AVP is likely to modulate the release of NPs and to 
regulate their receptors (natriuretic peptides receptor, NPR) 
activity [16–18]. N-terminal pro-brain natriuretic peptide 
(NT-proBNP), typically released both in response to acute 
heart damage (e.g., cardiac ischemia) and myocardial wall 
stretching, is the most used biochemical parameter among 
NPs in the clinical management of cardiopathic patients. 
Both NT-proBNP and copeptin represent stable and reliable 
markers, respectively, of BNP and AVP secretion; moreover, 
the combination of these two peptides accurately predicts 
mortality of patients affected by severe HF [19–21].
The primary aims of the present study were to estimate 
the incidence of PCVS after CPB surgery and to investi-
gate whether a presurgical impairment of the HPA axis was 
associated with PCVS. The secondary outcome was to study 
perioperative copeptin and NT-proBNP changes to explain 
their pathophysiological role in the onset of vasoplegia.
Materials and methods
Study design
We performed a prospective cohort study at the University 
Hospital “Città della Salute e della Scienza di Torino” in 
Turin, Italy. The local ethical committee “Comitato Etico 
Interaziendale” in Turin, approved the study protocol on 12 
October 2015 (protocol no. 0099127) and the study has been 
conducted in accordance with the Declaration of Helsinki.
Patients
All patients scheduled for CPB cardiac surgery and subse-
quent admission to the Cardiac Intensive Care Unit were 
consecutively evaluated for enrollment.
Estimating PCVS incidence equal to 20% of CPB inter-
ventions, a population of 50 patients was needed to obtain a 
95% CI of 10–33.7%.
Exclusions criteria were: age less than 18 years old, 
off-pump surgery, cardiac transplantation, extracorporeal 
membrane oxygenation, dialysis, end-stage hepatic disease, 
endocarditis, sepsis, septic shock, preoperative use of vaso-
pressors or positive inotropic drugs, chronic or even recent 
(within the last 2 weeks) corticosteroid therapy, bilateral 
adrenalectomy and lack of informed consent. All enrolled 
patients gave their consent to participate to the study.
Variables and data measurements
In the absence of a widely shared definition, PCVS was 
diagnosed for the simultaneous occurrence of a mean arte-
rial blood pressure (MAP) < 60  mmHg together with a 
systemic vascular resistance index (SVRI) < 1200 dyn.s/
cm5.m2, resulting in the need for a NE infusion with dos-
ages ≥ 0.1 µg/kg/min for at least 12 h and within the first 
24 h after cardiac surgery [1]. NE and epinephrine, but not 
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dDAVP, were the only vasoconstrictors administered as for 
clinical protocol in use in our Center.
Before surgery (T0), early in the morning, all patients 
underwent to HPA axis evaluation with both low-dose (LD) 
and standard-dose (SD) ACTH test as follows: after baseline 
cortisol measurement, i.v.  Cortrosyn® (cosyntropin, Ampha-
star Pharmaceuticals, Inc., Rancho Cucamonga, USA) 1 μg 
bolus was given with collection of venous blood sample for 
cortisol at 30 and 60 min; immediately after, i.v.  Cortrosyn® 
250 μg was administrated with cortisol measurement at 
120 min. A lack of response was defined for a peak cortisol 
level < 180 µg/L.
Moreover, at T0, 1 day (T1) and 7 days after surgery (T2), 
copeptin and NT-proBNP were measured together with rou-
tine biochemical analysis; at the same time, hemodynamic 
monitoring and NE infusion were recorded.
Demographic and clinical data were collected as follow-
ing: age, gender, EuroSCORE [22], SAPS II [23] and SOFA 
[24] score, type of surgery, CPB and cross clamping time, 
preoperative left ventricular ejection fraction (LVEF), anti-
hypertensive drugs assumed before surgery (if suspended or 
not), and renal failure (AKIN classification [25]). In addi-
tion, we evaluated if patients needed inotropic and/or vaso-
active drugs after CPB and dose.
Finally, the intensive care unit length of stay (ICU-LOS) 
was reported with follow-up at 28 days.
Copeptin determination
Blood from an ethylenediamine tetra-acetic acid (EDTA)-
containing tube was centrifugated at 4,000 rpm for 5 min 
and a plasma aliquot was immediately frozen and stored 
at  − 80 °C until analysis. Copeptin concentrations were 
determined with the B.R.A.H.A.M.S. KRYPTOR compact 
PLUS (ThermoFisher Scientific, Hennigsdorf, Germany) 
automated method. The limit of detection of the assay was 
0.9 pmol/L, while intra-assay coefficients of variation were 
below 7% and below 12% for inter-assay coefficients.
NT‑proBNP determination
Blood samples were collected in an EDTA-containing tube 
and processed on Cobas e602 automated platform (Roche 
Diagnostics), including centrifugation at 3500  rpm for 
5 min and determination by sandwich immunoassay with 
two monoclonal antibodies directed against N-terminal por-
tion (1–76) of proBNP molecule (Elecsys proBNP II), using 
electrochemiluminescence analysis. The limit of detection 
of the assay was 5 pg/mL (0.6 pmol/L), with a 5–35,000 
(0.6–4130) dynamic range as well as intra-assay and inter-
assay coefficients of variation of less than 5% at three dif-
ferent concentrations (46, 125 and 14,150).
Other determinations
All the routine laboratory measurements on serum, plasma 
and urine samples were performed with automated biochem-
ical assays in the local laboratory (Baldi & Riberi Labora-
tory, University Hospital “Città della Salute e della Scienza 
di Torino”, Turin, Italy).
Statistical analysis
All continuous variables were expressed as mean and 
standard deviation (SD) or median and interquartile range 
(IQR), while categorical variables were expressed as num-
ber and percentage (%). Inter-group comparisons for con-
tinuous variables were performed with the T test or the 
Wilcoxon–Mann–Whitney test depending on type of dis-
tribution. The Friedman test was used to identify longitu-
dinal differences. The χ2 test or the Fisher’s exact test were 
used to analyze categorical variables when appropriate; the 
Pearson coefficient was chosen to evaluate the correlation 
between continuous ones. The receiver-operating curves 
(ROC) analysis was used to assess copeptin and NT-proBNP 
cutoffs able to discriminate patients who developed PCVS. 
Logistic and linear regression models were calculated to 
identify possible predictors of PCVS among preoperative 
or intraoperative variables, as well as to define significant 
predictors of copeptin and NT-proBNP values over time. 
ICU-LOS was evaluated as outcome variable. Statistical 
analysis was performed using Stata/IC™ 14.2, version 29 
Jan 2018. Figures were made using GraphPad  Prism™, ver-
sion 8.01, and  MedCalc™, version 18.11.3.
Results
We consecutively evaluated 350 patients admitted to the car-
diac surgery ward; 253 of them were ineligible according 
with the exclusion criteria. Among the 97 eligible patients, 
55 were enrolled and completed the study (Fig. 1). All rel-
evant demographic variables and the main preoperative data 
are described in Table 1.
Among the included patients, 9 (16.3%) developed 
PCVS. Patients who developed PCVS had a significantly 
longer CPB and clamping time (p < 0.001); moreover, they 
needed more often inotropic support with NE or dobu-
tamine (p = 0.008) (Table 2). Mean dosage of dobutamine 
was slightly higher among patients who developed PCVS 
compared to those who did not (3.68 ± 2.92 µg/Kg/min vs. 
1.42 ± 1.96 µg/Kg/min; p = 0.01). The ICU-LOS was longer 
among PCVS compared to not-PCVS (3 days [2–8] vs. 1 day 
[1–2]); no patients died during the entire follow-up.
No pathological response to the SD ACTH test was 
recorded; moreover, no significant difference was observed 
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neither in basal nor in stimulated cortisol levels between 
patients who developed PCVS and those who did not 
(Table 1). Nevertheless, a greater proportion of patients 
developing PCVS (55.5 vs. 24%) presented a blunted 
response to the LD ACTH test, although this difference was 
not statistically significant.
Both copeptin and NT-proBNP significantly increased 
in the early postoperative respect to basal values. Copep-
tin at T1 (median 151.8 pmol/L [45.9–311.4]) was higher 
than at T0 (12.1 pmol/L [7.7–17.6]) and at T2 (12.1 pmol/L 
[8.7–21.3]; p < 0.0001). Differently, NT-proBNP levels 
increased significantly over the time (T0 median 598 pmol/L 
[155.5–1255], T1 median 659 pmol/L [276.2–1595.7]), T2 
median 1880 pmol/L [956.5–3309.5]); p < 0.0001).
Copeptin peak at T1 was similar in PCVS and not-
PCVS (Fig. 2). However, copeptin was significantly higher 
among PCVS both at T0 (19.2  pmol/L [17.89–21.29] 
vs. 11.39  pmol/L [6.33–14.78]; p < 0.001) and at T2 
(30.23 pmol/L [19.7–99.85] vs. 10.4 pmol/L [7.63–19.87]; 
p = 0.002) compared to not-PCVS (Fig. 2).
Finally, NT-proBNP was higher among PCVS at T0 
(1435 pg/mL [721.75–1836.25] vs. 365.5 pg/mL [141–977]; 
p = 0.006), at T1 (2,053 pg/mL [1365.25–3465.75] vs. 581 pg/
mL [220.5–1,259]; p = 0.003), and also at T2, although with-
out a clear significant difference (3571 pg/mL [1687.5–8316] 
vs. 1733 pg/mL [954–2957]; p = 0.06) (Fig. 3).
Despite the main role of AVP and NPs in hydro-electro-
lyte regulation, no significant difference was observed in 
serum sodium between the two groups at any time.
At T0, beta-blocker treatment was directly associ-
ated with NT-proBNP levels (r 0.53; p < 0.0001), without 
interfering with copeptin. At the same time, severe CKD 
(5 patients, 9.1%) was responsible for an increase in basal 
copeptin (r 0.39; p = 0.004) but not in NT-proBNP levels. 
Finally, diuretic treatment resulted directly associated both 
to basal NT-proBNP (r 0.46; p = 0.0004) and copeptin (r 
0.36; p = 0.008).
At T2, beta-blocker treatment was confirmed as a sig-
nificant predictor (OR 5.2, 95% CI 1.5–18.08) of elevated 
NT-proBNP levels (> 1880 pg/mL) along with mitral valve 
surgery (OR 3.88, 95% CI 1.1–13.6). At that time, NT-
proBNP showed a marked correlation with copeptin (r 0.88 
95% CI 0.8–0.93; p < 0.001) resulting also the best predictor 
(OR 1.0005, 95% CI 1.0001–1.001) of higher values of the 
glycopeptide (> 12 pmol/L), even considering diuretic treat-
ment. Noteworthy, this marked association was not evident 
either at T0 or at T1.
At univariate logistic analysis, basal copeptin (OR 1.17, 
95% CI 1.04–1.32) as well as CPB (OR 1.023, 95% CI 
1.005–1.04) and aortic clamp duration (OR 1.043, 95% 
CI 1.013–1.074) proved to be the best predictors of PCVS. 
Noteworthy, the association between basal copeptin and 
PCVS was confirmed at different multivariate models also 
including CPB (OR 1.15, 95% CI 1.009–1.32), clamping 
time (OR 1.16, 95% CI 0.996–1.36), severe CKD (OR 1.15, 
95% CI 1.021–1.31) or diuretic treatment (OR 1.17, 95% CI 
1.03–1.33).
The ROC analysis identified in a preoperative copeptin 
value > 16.9 pmol/L cutoff associated to the best accuracy 
(AUC 0.86, 95% CI 0.73–0.94, Se 0.89, 95% CI 0.52–1.00, 
Sp 0.86, 95% CI 0.73–0.95) and likelihood ratios (+ LR 
6.52, − LR 0.13) in predicting PCVS (Fig. 4). Similarly, the 
best preoperative cutoff for NT-proBNP was > 598 pg/mL 
(AUC 0.79, 95% CI 0.66–0.89, Se 0.89, 95% CI 0.52–1.00, 
Sp 0.61, 95% CI 0.45–0.75, + LR 2.27, − LR 0.18) (Fig. 5). 
The comparison of the two AUC did not show any signifi-
cant difference (difference 0.0682, 95% CI − 0.116 to 0.252, 
p = 0.47).
Discussion
We conducted a prospective study to evaluate possible neu-
roendocrine predictors of PCVS in a homogeneous cohort of 
cardiosurgical patients. The observed incidence of PCVS in 
our population (16.3%) reflects those previously reported in 
the literature [2–5, 26] and the complication was related to a 
significantly longer ICU-stay. Furthermore, the subgroup of 
patients who developed PCVS was comparable to the other 
in the prevalence of known risk factors such as reduced 
LVEF, ACE inhibitor treatment or valve surgery (Table 1). 
Therefore, our population was ideal to investigate the role 
of possible neuroendocrine determinants of this syndrome.
Fig. 1  Flow diagram illustrating the selection criteria
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Table 1  Demographic and 
preoperative variables
Continuous variables summarized as median and interquartile range (IQR), binary and categorical vari-
ables as absolute and percentage values
ACEi angiotensin-converting enzymes inhibitor, ARB angiotensin receptor blockers, BMI body mass index, 
CABG coronary artery bypass graft, CAD coronary artery disease, CKD chronic kidney disease, LVEF left 
ventricular ejection fraction, SAPS II simplified acute physiology score, SOFA sequential organ failure 
assessment
a Wilcoxon–Mann–Whitney test, p < 0.001
All (n = 55) PCVS (n = 9) Not-PCVS (n = 46)
Age (years) 72 (60–78) 76 (60–80) 71 (61–78)
Gender (female) 18 (38) 2 (22) 16 (35)
BMI (kg/m2) 25.12 (22.8–29) 21.9 (20.7–27.3) 25.3 (23.4–29)
EuroSCORE II 1.28 (0.98–1.83) 1.31 (0.88–1.68) 1.27 (1.03–1.83)
SAPS II 23 (19–28) 31 (19–35) 22 (19–26)
SOFA 4 (2–6) 8 (3–9) 4 (2–6)
LVEF (%) 60 (57–65) 61 (53–65) 60 (57–66)
Severe CKD 5 (9) 3 (33.3) 2 (4.3)a
ACEi 21 (38) 5 (55.5) 16 (34.8)
ARB 8 (14.5) 0 (0) 8 (17.4)
Beta-blockers 26 (47) 5 (55.5) 21 (45.6)
Diuretics 27 (49.1) 6 (66.6) 21 (45.6)
Diagnosis
 Mitral valve disease 26 (47) 7 (78) 19 (41)
 Aortic valve disease 29 (53) 5 (55.5) 24 (52)
 CAD 9 (16) 1 (11) 8 (17)
Surgery
 Mitral valve surgery 24 (43) 7 (78) 17 (37)
 Aortic valve surgery 29 (53) 5 (55.5) 24 (52)
 Combined valve surgery 7 (13) 3 (33.3) 4 (9)
 CABG 12 (22) 3 (33.3) 9 (19)
Cortisol (µg/L)
 ACTH test + 0’ 117 (87.1–149.1) 124 (57.2–144.7) 115 (90.3–149.1)
 ACTH test + 30’ 204 (164–241.3) 164 (113–211.2) 210.1 (165–245)
 ACTH test + 60’ 181.4 (146–219) 158 (121.3–182.5) 186.2 (147–226)
 ACTH test + 120’ 262.9 (231–329) 250 (200.7–255.3) 278 (232.9–329.5)
Table 2  Intra- and postoperative 
variables
Continuous variables summarized as median and interquartile range (IQR), binary and categorical vari-
ables as absolute and percentage values
CLAMP clamping time, CPB cardiopulmonary bypass
a Wilcoxon–Mann–Whitney test, p < 0.001
b Fisher’s exact test, p = 0.008
All (n = 55) PCVS (n = 9) Not-PCVS (n = 46)
CPB (min) 132 (108–158) 170 (149–209) 131 (105–145)a
CLAMP (min) 99.5 (82.5–117.5) 137.5 (111–172) 97 (82–107)a
Hemodynamic support
 Nor-epinephrine 21 (38) 7 (78) 16 (35)b
 Epinephrine 4 (7) 2 (22) 2 (4)
 Dobutamine 18 (33) 6 (66) 12 (26)b
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We found a non-significantly higher percentage of 
cases of reduced response to preoperative LD ACTH test 
among patients who developed PCVS. The Society of Criti-
cal Care Medicine and the European Society of Intensive 
Care Medicine have provided an indication in favor of a 
short-term prophylactic treatment with hydrocortisone in 
cardiopathic subjects undergoing on-pump surgery [9]. In 
fact, hydrocortisone, readily available as cortisol, is the only 
synthetic steroid that has been shown to reduce operative 
complications such as atrial fibrillation and patient mortal-
ity, likely avoiding a Critical Illness Related Corticosteroid 
Insufficiency (CIRCI) induced by CPB [9]. Unfortunately, 
our study design did not include a postoperative HPA axis 
re-evaluation, to define whether these patients developed a 
CPB-induced CIRCI, although it apparently did not hesitate 
in an overt PCVS. However, subjects with an history of com-
promised HPA axis remain to be considered at increased risk 
Fig. 2  Copeptin at different observation times, patients affected 
by post-cardiac surgery vasoplegia (PCSV) versus not-PCSV 
(*p < 0.001; §p = 0.002)
Fig. 3  NT-proBNP at different observation times, patients affected 
by post-cardiac surgery vasoplegia (PCSV) versus not-PCSV 
(*p = 0.006; §p = 0.003)
Fig. 4  Receiver-operating curve (ROC) analysis calculated for copep-
tin at T0 associated to the best preoperative cutoff
Fig. 5  Receiver-operating curve (ROC) analysis calculated for NT-
proBNP at T0 associated to the best preoperative cutoff
1539Journal of Endocrinological Investigation (2021) 44:1533–1541 
1 3
for relative corticosteroid insufficiency in case of on-pump 
surgery.
The other main result of our research is the novel descrip-
tion of two different trends for copeptin and NT-proBNP in 
the perioperative of such major cardiac interventions. Both 
are significantly influenced by diuretic therapy in the pre-
operative period; copeptin is also higher in patients with 
reduced renal clearance, as expected, while NT-proBNP in 
those with mitral insufficiency and treated with beta-block-
ers. Starting immediately after surgery, they take different 
paths, determined by equally different factors. On the one 
hand, copeptin is confirmed as an excellent marker of acute 
stress [27, 28], recording a transient tenfold increase in the 
early postoperative compared to basal values (Fig. 2). On 
the other, NT-proBNP immediately reveals the mechanical 
stress involving the myocardium, remaining elevated even 
at 7 days (Fig. 3) particularly in those patients who have 
undergone a procedure involving the valve system.
The further analysis of the PCVS subpopulation still pro-
vides new information. First, copeptin confirms its qualities 
as a prognostic factor in patients suffering from HF, predict-
ing already at baseline the onset of PCVS. This significant 
association is confirmed by regression analyses also consid-
ering interfering therapy with diuretics, severe CKD comor-
bidity or other well-known determinants of the syndrome 
such as CPB or clamping time.
Second, our data do not reveal a blunted glycopep-
tide peak in the immediate postoperative period of PCVS 
patients, as previously described [5]. Therefore, no evident 
defect in AVP production is to be suspected in the first post-
operative day in case of post-cardiotomic vasoplegia, espe-
cially considering the good correlation between AVP and 
copeptin values previously described during vasodilatory 
shock [5].
Third, PCVS patients present copeptin levels at 1-week 
post-surgery almost 50% increased compared to basal ones, 
unlike non-PCVS. At that time, a strong correlation becomes 
evident among NT-proBNP and copeptin, even considering 
diuretic treatment; conversely, these reliable biomarkers of 
HF progression were not significantly related to each other 
neither in the preintervention, nor in the early postoperative.
From this point of view, it seems that CPB surgery 
retraces the neuroendocrine dysregulation observed in 
severe HF over a truly short period of time. It is not sur-
prising considering that, in few hours, the cardiovascular 
system of PCVS subjects experiences a prolonged aortic 
clamp, a complex surgical procedure and a sustained shock 
induced by endothelial inflammation. Moreover, this novel 
observation is consistent with the postulated baroreflex 
dysregulation during intense vascular stress and could be 
the result of a rapid aggravation of V1R desensitization 
[13]. In fact, the eventual damage of high-pressure baro-
receptors, responsible for the physiological AVP release 
inhibition, together with the SIRS-related dysregulation in 
V1R and NPR may be implicated in the observed increase 
in copeptin and NT-proBNP levels.
This hypothesis implies some other important 
considerations.
It is possible that long-term monitoring of copeptin in 
the postoperative of PCVS may be useful to assess the 
good result of the procedure and patient’s prognosis. In 
fact, a persistent elevation of this biomarker, able to pre-
dict cardiopathic patients’ mortality even in the absence 
of clinical signs of disease progression [20], could suggest 
a tighter follow-up because of a possible worse outcome.
Most of all, the increase in copeptin levels at baseline 
could reveal an advanced stage in the V1R desensitiza-
tion process as described in severe HF, thus predicting the 
enormous need for AVP during the PCVS to overcome a 
rapidly increasing peripheral insensitivity. Recently, sev-
eral studies have suggested that the use of 1-desamino-8-d-
arginine-vasopressin (dDAVP) in this setting would reduce 
the need for high doses of NE and related adverse effects 
[29]. A recent meta-analysis showed that the precocious 
administration of low dose of dDAVP would reduce the 
rate of perioperative complications in patients undergoing 
elective and emergency cardiac surgery (OR 0.33, 95% 
CI 0.20–0.54) [30]. Although a wide heterogeneity was 
present among the selected papers, the VANCS trial, a 
double-blind randomized controlled study characterized 
by the largest sample size, showed a significant reduc-
tion in mortality and in postoperative complications in 
patients treated with dDAVP (0.01–0.06 UI/min) instead 
of NE (10–60 μg/min) in case of postoperative vasoplegia 
(unadjusted HR 0.55, 95% CI 0.38–0.80; p = 0.0014) [31].
In this context, our data offer a new and more accu-
rate preoperative copeptin cutoff to predict PCVS 
(> 16.9 pmol/L). In 2011, Colson et al. [26] have already 
suggested that preoperative copeptin  > 9.43 pmol/L could 
predict CPB-related vasoplegia. Nevertheless, in their 
cohort, PCVS as well as higher copeptin levels resulted 
associated to higher cardiovascular functional class, signif-
icantly reduced LVEF and hyponatremia; thus, suggesting 
that post-surgical PCVS is simply predicted by severe HF. 
Instead, the present copeptin cutoff is not only character-
ized by an acceptable accuracy and likelihood ratios (AUC 
0.86, − LR 0.13), but also is obtained from a homogeneous 
cohort of cardiopathic patients with preserved LVEF.
Our research has some limitations. First, the protocol was 
designed to perform the ACTH tests 24 h before surgery, so 
patients hospitalized on the day of surgery and emergencies 
were excluded from the study. Second, no HPA axis evalu-
ation was repeated in the first day after the intervention to 
identify possible CPB-related CIRCI. Finally, the number of 
PCVS subjects is relatively small, imposing a limited num-
ber of covariates at regression analysis.
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Conclusion
Preoperative secondary corticosteroid insufficiency is not an 
evident risk factor for PCVS and a routinely assessment of 
HPA axis function might be useless. Nevertheless, hydro-
cortisone prophylactic treatment in patients undergoing CPB 
surgery should be considered because of the high risk of 
CIRCI induced by extracorporeal circulation. Basal preop-
erative copeptin predicts in our cohort the occurrence of 
PCVS more accurately than previously reported risk fac-
tors. Routine evaluation of preoperative copeptin could be 
considered to identify high-risk subjects who deserve to be 
treated with dDAVP in case of vasoplegia.
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